
Due to an increase in demands, AGC Biologics now chooses to establish a new factory at around DKK 1.2bn (USD 195.2m), which more than doubles the firm's Danish production capacity, according to AGC Biologics' Vice President, Technical Operations, Christian Christensen.
"This basically revolves around the demands having surpassed our current production capacity," he tells MedWatch, thereby outlining the primary reason why the contract manufacturer plans to establish the new factory at 19,000 m2 near the firm's existing factory facility.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app